Odagaki Yuji, Toyoshima Ryoichi
Department of Psychiatry, Saitama Medical School, 38 Morohongo, Moroyama-machi, Iruma-gun, Staitama 350-0495, Japan.
Naunyn Schmiedebergs Arch Pharmacol. 2006 Feb;372(5):335-45. doi: 10.1007/s00210-006-0041-x. Epub 2006 Feb 21.
Receptor-mediated guanine nucleotide-binding regulatory protein (G protein) activation or functional coupling between receptors and G proteins has been investigated by means of agonist-induced [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPgammaS) binding, especially for the receptor subtypes negatively coupled to adenylyl cyclase through Gi type G proteins. In the present study, 5-HT-stimulated [35S]GTPgammaS binding to rat stritatal membranes was pharmacologically characterized in detail with the help of an extensive series of 5-HT receptor ligands. The optimum experimental conditions for the concentrations of GDP, MgCl2 and NaCl in the assay buffer were initially determined, and the standard assay was performed with 20 microM GDP, 5 mM MgCl2 and 100 mM NaCl. The specific [35S]GTPgammaS binding was stimulated by several compounds that had been shown to be agonists at 5-HT(1B/1D) receptors. The negative logarithmic values of the concentration eliciting half-maximal effect (pEC50) for these agonists were significantly correlated with their pKi's reported in the previous study of 5-HT1B receptor binding in rat frontal cortical membranes. The increase in specific [35S]GTPgammaS binding in response to 1 microM 5-HT was potently inhibited by several 5-HT(1B/1D) receptor antagonists as well as beta-adrenoceptor antagonists such as S(-)-cyanopindolol. On the other hand, 3-[4-(4-chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol HCl (BRL15572), a selective antagonist against human 5-HT1D receptors, was inactive as an antagonist at least up to 1 microM. Additionally, the concentration-response curve for 2-[5-[3-(4-methylsulphonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine (L694247) was shifted rightward in parallel by the addition of S(-)-cyanopindolol at concentrations of 10 and 100 nM, indicative of the competitive inhibitory manner. The specific [35S]GTPgammaS binding was reduced by 1'-methyl-5-([2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl)-2,3,6,7-tetrahydrospirospiro(furo[2,3-f]indole-3,4'-piperidine) (SB224289) and methiothepin in a concentration-dependent manner. The inhibitory curve by either compound was shifted to the right by 10 and 100 nM S(-)-cyanopindolol, suggesting that these two drugs behaved as inverse agonists at 5-HT1B receptors in the present functional assay system. 5-HT-stimulated [35S]GTPgammaS binding to rat striatal membranes serves as a simple but useful method of investigating the functional interaction between the native 5-HT1B receptors and their coupled G proteins in this brain region.
受体介导的鸟嘌呤核苷酸结合调节蛋白(G蛋白)激活或受体与G蛋白之间的功能偶联已通过激动剂诱导的[35S]鸟苷-5'-O-(3-硫代)三磷酸([35S]GTPγS)结合进行了研究,特别是对于通过Gi型G蛋白与腺苷酸环化酶负偶联的受体亚型。在本研究中,借助一系列广泛的5-羟色胺(5-HT)受体配体,对5-HT刺激的[35S]GTPγS与大鼠纹状体膜的结合进行了详细的药理学表征。首先确定了测定缓冲液中GDP、MgCl2和NaCl浓度的最佳实验条件,标准测定在20μM GDP、5 mM MgCl2和100 mM NaCl条件下进行。几种已被证明是5-HT(1B/1D)受体激动剂的化合物刺激了特异性[35S]GTPγS结合。这些激动剂产生半数最大效应的浓度的负对数值(pEC50)与先前大鼠额叶皮质膜中5-HT1B受体结合研究中报道的它们的pKi值显著相关。1μM 5-HT引起的特异性[35S]GTPγS结合增加被几种5-HT(1B/1D)受体拮抗剂以及β-肾上腺素能受体拮抗剂如S(-)-氰基吲哚洛尔有效抑制。另一方面,3-[4-(4-氯苯基)哌嗪-1-基]-1,1-二苯基-2-丙醇盐酸盐(BRL15572),一种针对人5-HT1D受体的选择性拮抗剂,至少在1μM时作为拮抗剂无活性。此外,2-[5-[3-(4-甲基磺酰氨基)苄基-1,2,4-恶二唑-5-基]-1H-吲哚-3-基]乙胺(L694247)的浓度-反应曲线在加入10和100 nM浓度的S(-)-氰基吲哚洛尔后平行右移,表明其为竞争性抑制方式。特异性[35S]GTPγS结合被1'-甲基-5-([2'-甲基-4'-(5-甲基-1,2,4-恶二唑-3-基)联苯-4-基]羰基)-2,3,6,7-四氢螺螺(呋喃[2,3-f]吲哚-3,4'-哌啶)(SB224289)和甲硫哒嗪以浓度依赖性方式降低。两种化合物的抑制曲线在10和100 nM S(-)-氰基吲哚洛尔作用下均右移,表明在本功能测定系统中这两种药物在5-HT1B受体上表现为反向激动剂。5-HT刺激的[35S]GTPγS与大鼠纹状体膜的结合是研究该脑区天然5-HT1B受体与其偶联的G蛋白之间功能相互作用的一种简单而有用的方法。